Abstract:Abstract Background Colorectal carcinoma (CRC) is the third most common cancer and second most common cause of cancer-related deaths worldwide. Ribonucleic acid (RNA) N6-methyladnosine (m6A) and methyltransferase-like 3 (METTL3) play key roles in cancer progression. However, the roles of m6A and METTL3 in CRC progression require further clarification. Methods Adenoma and CRC samples were examined to detect m6A and METTL3 levels, and tissue microarrays were performed to evaluate the association of m6A and METTL3 levels with the survival of patients with CRC. The biological functions of METTL3 were investigated through cell counting kit-8, wound healing, and transwell assays. M6A epitranscriptomic microarray, methylated RNA immunoprecipitation-qPCR, RNA stability, luciferase reporter, and RNA immunoprecipitation assays were performed to explore the mechanism of METTL3 in CRC progression. Results M6A and METTL3 levels were substantially elevated in CRC tissues, and patients with CRC with a high m6A or METTL3 levels exhibited shorter overall survival. METTL3 knockdown substantially inhibited the proliferation, migration, and invasion of CRC cells. An m6A epitranscriptomic microarray revealed that the cell polarity regulator Crumbs3 (CRB3) was the downstream target of METTL3. METTL3 knockdown substantially reduced the m6A level of CRB3, and inhibited the degradation of CRB3 mRNA to increase CRB3 expression. Luciferase reporter assays also showed that the transcriptional level of wild-type CRB3 significantly increased after METTL3 knockdown but not its level of variation. Knockdown of YT521-B homology domain–containing family protein 2 (YTHDF2) substantially increased CRB3 expression. RNA immunoprecipitation assays also verified the direct interaction between the YTHDF2 and CRB3 mRNA, and this direct interaction was impaired after METTL3 inhibition. In addition, CRB3 knockdown significantly promoted the proliferation, migration, and invasion of CRC cells. Mechanistically, METTL3 knockdown activated the Hippo pathway and reduced nuclear localization of Yes1-associated transcriptional regulator, and the effects were reversed by CRB3 knockdown. Conclusions M6A and METTL3 levels were substantially elevated in CRC tissues relative to normal tissues. Patients with CRC with high m6A or METTL3 levels exhibited shorter overall survival, and METTL3 promoted CRC progression. Mechanistically, METTL3 regulated the progression of CRC by regulating the m6A–CRB3–Hippo pathway.

METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding

METTL3 Promotes Tumour Development by Decreasing APC Expression Mediated by APC Mrna N 6-Methyladenosine-dependent YTHDF Binding

METTL3 Regulates the Malignancy of Cervical Cancer Via Post-Transcriptional Regulation of RAB2B

METTL3/YTHDF2 M6a Axis Accelerates Colorectal Carcinogenesis Through Epigenetically Suppressing YPEL5.

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

METTL3 Promotes OSCC Progression by Down-Regulating WEE1 in a m6A-YTHDF2-Dependent Manner

The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma

METTL3 promotes colorectal carcinoma progression by regulating the m6A–CRB3–Hippo axis

METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway

IDDF2018-ABS-0233 N6-adenosine Methyltransferase METTL3 Promotes Tumour Metastasis Via SOX2 MRNA M6A Modification in Colorectal Carcinoma

N6-methyladenosine Methyltransferase METTL3 Promotes Colorectal Cancer Cell Proliferation Through Enhancing MYC Expression.

METTL3 Facilitates Tumor Progression by COL12A1/MAPK Signaling Pathway in Esophageal Squamous Cell Carcinoma

METTL3 Preferentially Enhances Non-M6a Translation of Epigenetic Factors and Promotes Tumourigenesis

m 6 A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways.

METTL3‐mediated m6A modification of EPPK1 to promote the development of esophageal cancer through regulating the PI3K/AKT pathway

METTL3 is Associated with the Malignancy of Esophageal Squamous Cell Carcinoma and Serves As a Potential Immunotherapy Biomarker.

METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway

METTL3 mediated m 6 A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ΔNp63.

METTL3 Inhibits Antitumor Immunity by Targeting M6a-Bhlhe41-cxcl1/cxcr2 Axis to Promote Colorectal Cancer.

METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8

METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA